Complying with the European Clinical Trials directive while surviving the administrative pressure - an alternative approach to toxicity registration in a cancer trial.
about
Genomic profiling of thousands of candidate polymorphisms predicts risk of relapse in 778 Danish and German childhood acute lymphoblastic leukemia patients.Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites.Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy.Cerebellar mutism syndrome in children with brain tumours of the posterior fossaHypertriglyceridemia during asparaginase treatment in children with acute lymphoblastic leukemia correlates with antithrombin activity in adolescents.Prospective study of thromboembolism in 1038 children with acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology (NOPHO) study.DNA Methylation Adds Prognostic Value to Minimal Residual Disease Status in Pediatric T-Cell Acute Lymphoblastic Leukemia.Parents' and Adolescents' Preferences for Intensified or Reduced Treatment in Randomized Lymphoblastic Leukemia Trials.The effect of central nervous system involvement and irradiation in childhood acute lymphoblastic leukemia: Lessons from the NOPHO ALL-92 and ALL-2000 protocols.Asparaginase-associated pancreatitis is not predicted by hypertriglyceridemia or pancreatic enzyme levels in children with acute lymphoblastic leukemia.Hyperlipidemia is a risk factor for osteonecrosis in children and young adults with acute lymphoblastic leukemia.Cerebral sinus venous thromboses in children with acute lymphoblastic leukaemia - a multicentre study from the Nordic Society of Paediatric Haematology and Oncology.Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation.Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.The association between glucocorticoid therapy and BMI z-score changes in children with acute lymphoblastic leukemia.Early presentation of osteonecrosis in acute lymphoblastic leukemia: Two children from the Nordic and Baltic cohort.Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia.Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol.Cancer care in the developed world: A comparison of surgical oncology training programs.Toxicity profile and treatment delays in NOPHO ALL2008-comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia.A novel chemosensitivity profiling platform for small acute lymphoblastic leukemia cell populations.Children with low-risk acute lymphoblastic leukemia are at highest risk of second cancers.Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years.
P2860
Q31170949-23D1F522-7588-4827-BC2E-6F3BB9996323Q33441148-CE81D3B5-7212-44FC-A750-777DD5CFD47BQ33557148-F2D7577D-AB6A-497F-97B8-671B71340808Q33823735-95DB66B9-1E98-4A28-8986-12F27C29FC32Q38821455-50ABC644-93A5-4471-9B59-0ACECD0B010BQ38927735-F2BC02B9-D57B-445C-BD03-A9F35A6F09B2Q39958090-1E66D7A2-0095-4A79-9C97-B362416379CBQ40158198-D15D12F0-429A-4DEF-B739-936122CB3794Q40539062-3DA2245A-19E9-44BF-9102-EF7AE87EFD1CQ40609832-49B1824A-5004-44E8-AE4D-CDD03B9206EDQ42336342-70436D84-7705-4F87-815D-4C2B88AD50CDQ44792736-058851C1-0531-417B-9BA7-5F7B54ABCF3EQ48203946-C13C5BF5-6E92-49F8-A804-945246ED749FQ50501063-2D245146-EFAD-420B-85C7-86737AB906C3Q50561839-7740B6FE-50AB-45C7-A665-C5294EA93B01Q50638089-1EC31F8D-F720-4ED3-A5F9-19704B7F0933Q51530980-4A6FE728-B2CD-4334-84D5-1172B8806994Q51620499-261ADBF7-B642-4EA7-BC47-E339D03BC817Q53218164-803DB3D4-9FBB-4908-9D4B-82E259CBA0D8Q53544852-F309F0ED-417F-4117-92CA-D5645D1E503BQ53662426-6E2728B4-3F79-44AC-9DB2-72FD23ED2B96Q54231400-7DB80723-29B0-404E-ABB7-B46C9816602CQ55383390-39DA6257-9EE6-4D37-B951-168AD0BC2F64
P2860
Complying with the European Clinical Trials directive while surviving the administrative pressure - an alternative approach to toxicity registration in a cancer trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Complying with the European Cl ...... egistration in a cancer trial.
@en
Complying with the European Cl ...... egistration in a cancer trial.
@nl
type
label
Complying with the European Cl ...... egistration in a cancer trial.
@en
Complying with the European Cl ...... egistration in a cancer trial.
@nl
prefLabel
Complying with the European Cl ...... egistration in a cancer trial.
@en
Complying with the European Cl ...... egistration in a cancer trial.
@nl
P2093
P50
P1476
Complying with the European Cl ...... egistration in a cancer trial.
@en
P2093
Ann Åsberg
Birgitte Vilsbøll Hansen
Goda Vaitkeviciene
Helena Hallböök
Henrik Birgens
Kaie Pruunsild
Laimonas Griškevičius
Louise Helt
Mats Heyman
P304
P356
10.1016/J.EJCA.2013.09.027
P577
2013-11-11T00:00:00Z